Equities analysts expect Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) to announce sales of $1.88 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.10 million and the highest estimate coming in at $2.33 million. Tetraphase Pharmaceuticals reported sales of $1.49 million in the same quarter last year, which indicates a positive year-over-year growth rate of 26.2%. The business is expected to report its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $1.88 million for the current fiscal year, with estimates ranging from $5.00 million to $12.31 million. For the next fiscal year, analysts expect that the company will post sales of $19.39 million per share, with estimates ranging from $8.70 million to $46.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.18. The business had revenue of $2.53 million for the quarter, compared to analyst estimates of $2.26 million. Tetraphase Pharmaceuticals had a negative return on equity of 90.75% and a negative net margin of 1,187.17%.
Shares of TTPH stock opened at $3.18 on Friday. The firm has a market cap of $157.36, a P/E ratio of -1.21 and a beta of 2.61. Tetraphase Pharmaceuticals has a twelve month low of $2.05 and a twelve month high of $8.75.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total transaction of $54,425.00. Following the transaction, the insider now directly owns 8,750 shares of the company’s stock, valued at approximately $54,425. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.50% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter valued at about $107,000. Cubist Systematic Strategies LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter valued at about $195,000. Paloma Partners Management Co acquired a new position in shares of Tetraphase Pharmaceuticals in the 4th quarter valued at about $210,000. American International Group Inc. lifted its stake in shares of Tetraphase Pharmaceuticals by 44.1% in the 3rd quarter. American International Group Inc. now owns 33,826 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 10,345 shares during the period. Finally, Virtus Fund Advisers LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the 4th quarter valued at about $376,000. 58.50% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://dakotafinancialnews.com/2018/04/13/tetraphase-pharmaceuticals-inc-ttph-expected-to-post-quarterly-sales-of-1-88-million.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.